Ensysce Biosciences (ENSC) Other Non-Current Assets (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Other Non-Current Assets of $83332.0 for Q4 2025, down 67.0% year-over-year from $252550.0 in Q4 2024, and down 34.67% quarter-over-quarter from $127551.0 in Q3 2025.
Ensysce Biosciences (ENSC) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Other Non-Current Assets for 6 consecutive years, with $83332.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets fell 67.0% year-over-year to $83332.0; the TTM figure through Dec 2025 stood at $83332.0 (down 67.0% YoY), while the FY2025 annual figure was $83332.0, down 67.0% from the prior year.
- Other Non-Current Assets declined to $83332.0 in Q4 2025 per ENSC's latest filing, from $127551.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $838091.0 in Q2 2021 and bottomed at $83332.0 in Q4 2025.
- Historically, Other Non-Current Assets has averaged $467837.3 across 5 years, with a median of $460883.0 in 2023.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets surged 19867.09% — and 2025, when it plunged 67.0%.
- Ensysce Biosciences' Other Non-Current Assets stood at $754756.0 in 2021, then slipped by 22.37% to $585883.0 in 2022, then fell by 28.45% to $419217.0 in 2023, then sank by 39.76% to $252550.0 in 2024, then slumped by 67.0% to $83332.0 in 2025.
- Business Quant data shows ENSC's Other Non-Current Assets at $83332.0 in Q4 2025, $127551.0 in Q3 2025, and $292860.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | 83,332.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 83,332.00 |
| Sep 30, 2025 | 127,551.00 |
| Jun 30, 2025 | 292,860.00 |
| Mar 31, 2025 | 210,883.00 |
| Dec 31, 2024 | 252,550.00 |
| Sep 30, 2024 | 294,217.00 |
| Jun 30, 2024 | 335,883.00 |
| Mar 31, 2024 | 377,550.00 |
| Dec 31, 2023 | 419,217.00 |
| Sep 30, 2023 | 460,883.00 |
| Jun 30, 2023 | 502,550.00 |
| Mar 31, 2023 | 544,217.00 |
| Dec 31, 2022 | 585,883.00 |
| Sep 30, 2022 | 627,550.00 |
| Jun 30, 2022 | 671,423.00 |
| Mar 31, 2022 | 713,090.00 |
| Dec 31, 2021 | 754,756.00 |
| Sep 30, 2021 | 796,423.00 |
| Jun 30, 2021 | 838,091.00 |
| Dec 31, 2020 | 3,780.00 |